ReviewMedComm2021
Lipid metabolism in cancer progression and therapeutic strategies.
Review in MedComm, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 241 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
241 citing papers in PubMed, 2 syntheses or guidelines pooled it, 346 citations in OpenAlex.
- Effects of different exercise prescription parameters on metabolic and inflammatory biomarkers in cancer patients: a systematic review, meta-analysis, and meta-regression.Frontiers in immunology · 2025Pooled it
- Non-small cell lung cancer and metabolism research from 2013 to 2023: a visual analysis and bibliometric study.Frontiers in oncology · 2024Pooled it
- Stable Isotope-Resolved Metabolomics in Elucidating Mitochondrial Metabolic Reprogramming and Therapeutic Targets.Biomedical chromatography : BMC · 2026Review
- Article
- Article
- Integrative Multi-Omics Reveal Metabolic Reprogramming by Ketogenic Diet in Melanoma Xenografts.Biomolecules · 2026Article
- Multi-Omics Profiling in a Symptomatic Cohort Identifies Coordinated Biomarker Signatures in Ovarian Cancer Serum.Diagnostics (Basel, Switzerland) · 2026Article
- A comprehensive plasma-based approach to thromboinflammation in bladder cancer: integrating lipidomics, thrombin generation, and NETosis biomarkers.Journal of translational medicine · 2026Article
- Identification of Circulating Lipidomic Biomarkers of Malnutrition Risk among Oncology Patients in the Total Cancer Care (TCC) Study: A Cross-Sectional Analysis.The Journal of nutrition · 2026Article
- Role of Ferredoxin 1Cancer pathogenesis and therapy · 2026Review
- Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia.Cell death & disease · 2026Article
- Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity.Experimental hematology & oncology · 2026Review
- The nutrigenomic-epigenetic axis in cancer: from dietary bioactives to precision oncology.Nutrition & metabolism · 2026Review
- IGF2BP3 promotes epithelial ovarian cancer progression by regulating FASN expression.Scientific reports · 2026Article
- Revisiting the Lipid-Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology.Biomolecules · 2026Review
- Chemopreventive Potential of Brucine-Gold Nanoparticles (BRU-AuNPs) in DMBA-induced Mammary Cancer via Modulation of PI3K/AKT/mTOR Pathway.Applied biochemistry and biotechnology · 2026Article
- Fatty Acids in Cancer Therapy: Chemical Conjugates, Nanocarriers, and Therapeutic Opportunities.Molecules (Basel, Switzerland) · 2026Review
- Germline APOE ε2 homozygosity and reduced risk of breast cancer: a population-based cohort study.Breast cancer research : BCR · 2026Article
- Curcumin as a ceramide metabolism-targeting agent: Molecular mechanisms and therapeutic implications in cancer.Molecular biology reports · 2026Review
- Lipidome Analysis of Cancer Cells and Their Extracellular Vesicles Reveals Cancer-Type-Specific Lipid Signatures and Enables the Design of EV-Mimetic Liposomes.Journal of extracellular vesicles · 2026Article
181 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated lipid metabolism represents an important metabolic alteration in cancer. Fatty acids, cholesterol, and phospholipid are the three most prevalent lipids that act as energy producers, signaling molecules, and source material for the biogenesis of cell membranes. The enhanced synthesis, storage, and uptake of lipids contribute to cancer progression. The rewiring of lipid metabolism in cancer has been linked to the activation of oncogenic signaling pathways and cross talk with the tumor microenvironment. The resulting activity favors the survival and proliferation of tumor cells in the harsh conditions within the tumor. Lipid metabolism also plays a vital role in tumor immunogenicity via effects on the function of the noncancer cells within the tumor microenvironment, especially immune-associated cells. Targeting altered lipid metabolism pathways has shown potential as a promising anticancer therapy. Here, we review recent evidence implicating the contribution of lipid metabolic reprogramming in cancer to cancer progression, and discuss the molecular mechanisms underlying lipid metabolism rewiring in cancer, and potential therapeutic strategies directed toward lipid metabolism in cancer. This review sheds new light to fully understanding of the role of lipid metabolic reprogramming in the context of cancer and provides valuable clues on therapeutic strategies targeting lipid metabolism in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.